Aclaris Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Aclaris Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- ACRS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001557746
Board of directors
-
Anand Mehra · DirectorSince 2023
-
Andrew Kenneth William Powell · DirectorSince 2023
-
Andrew N. Schiff · DirectorSince 2023
-
Bryan M. Reasons · DirectorSince 2023
-
Christopher P. Molineaux · DirectorSince 2023
-
Douglas J. Manion · Director · Pres and CEOSince 2023
-
Hugh M. Davis · Director · President and COOSince 2024
-
Maxine Gowen · DirectorSince 2023
-
Neal Walker · Director · CEOSince 2023
-
Vincent Milano · DirectorSince 2023
-
William D. Humphries · DirectorSince 2023
Chief executives
Douglas J. Manion
· Pres and CEO
Dates unknown
Dates unknown
Board connections
4 of this board's directors also sit on 4 other boards.
- via Neal Walker
- via Vincent Milano
- via Andrew N. Schiff
- via Maxine Gowen
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $1,359,000
- 1 sale by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 1, 2026 | Kolbeck Roland Wilhelm Officer (Chief Scientific Officer) | Option exercise | +36,375 | — | — |
| Aug 1, 2026 | Kolbeck Roland Wilhelm Officer (Chief Scientific Officer) | Shares withheld for tax | −12,385 | $5.20 | $64,402 |
| Jun 5, 2026 | Andrew N. Schiff Director | Option exercise | +11,580 | — | — |
| Jun 5, 2026 | Christopher P. Molineaux Director | Option exercise | +11,580 | — | — |
| Jun 5, 2026 | Vincent Milano Director | Option exercise | +11,580 | — | — |
| Jun 5, 2026 | Anand Mehra Director | Option exercise | +11,580 | — | — |
| Jun 5, 2026 | William D. Humphries Director | Option exercise | +11,580 | — | — |
| Jun 5, 2026 | Maxine Gowen Director | Option exercise | +11,580 | — | — |
| May 1, 2026 | Hall Jesse Wayne Officer (Chief Medical Officer) | Option exercise | +36,375 | — | — |
| May 1, 2026 | Hall Jesse Wayne Officer (Chief Medical Officer) | Shares withheld for tax | −9,330 | $4.41 | $41,145 |
| Apr 23, 2026 | Leonard Braden Michael 10% owner | Open-market sale | −300,000 | $4.53 | $1,359,000 |
| Mar 1, 2026 | Balthaser Kevin Officer (Chief Financial Officer) | Option exercise | +2,375 | — | — |
| Mar 1, 2026 | Balthaser Kevin Officer (Chief Financial Officer) | Shares withheld for tax | −677 | $2.87 | $1,943 |
| Feb 3, 2026 | Loerop James Officer (Chief Business Officer) | Option exercise | +20,875 | — | — |
| Feb 3, 2026 | Neal Walker Director, Officer (CEO) | Option exercise | +63,475 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.